Felipe Bedoya, Ph.D.

Felipe Bedoya is a seasoned professional in the field of process development and CMC of CAR and TCR T-cell immunotherapies with experience in large-scale cGMP manufacturing for clinical applications.

He specializes in genome engineering, including gene editing and vector-free gene insertion for next-generation cellular therapies, and implements CRISPR and Meganuclease platforms.

Felipe excels in operational validation and implementing specialized large-scale systems for manufacturing cell therapies.

His expertise includes using systems like XURI/Wave, CliniMACS Prodigy, G-Rex Bioreactors, Elutra, CS5, CS Elite, and more for cell separation and purification.

He is well-versed in DOE approaches for assessing process performance qualification, change controls, and validations.

Felipe's analytical development skills cover in vitro and in vivo characterization of cellular products like CAR-T and TCR-T cells to determine potency, persistence, and efficacy.

Education-wise, Felipe holds a Ph.D. in Molecular Medicine/Immunology and an M.Sc. in Biomedical Sciences from the University of South Florida, among other qualifications.

Throughout his career, he has held key positions at prestigious organizations such as Tmunity Therapeutics Incorporated, Takeda, bluebird bio, and Harvard Medical School.